Redcare Pharmacy’s CCO Exit Casts a Shadow Over Its Upcoming Profitability Check

CCO Dirk Brüse resigns abruptly ahead of Redcare's full Q1 report on May 6, testing margins and cash flow amid oversold stock and rising OTC competition.

The online pharmacy is navigating a turbulent stretch, with a surprise departure in the C-suite colliding with a pivotal moment for its financial credibility. On May 6, Redcare Pharmacy will release its full first-quarter report, offering investors the first detailed look at margins and cash flow after a period of heavy spending. But the abrupt resignation of Chief Commercial Officer Dirk Brüse, effective immediately on Tuesday, has injected an unwelcome dose of uncertainty into the narrative.

A Leadership Vacuum at a Critical Juncture

Brüse, a key architect of Redcare’s European expansion, stepped down for personal reasons, leaving a void in the commercial leadership. CEO Olaf Heinrich has taken over the commercial portfolio on an interim basis, assuming direct responsibility for sales growth, partnerships, and marketing while the search for a permanent successor begins. The move is designed to signal stability, but it also piles operational pressure onto a CEO already steering the company through a margin-recalibration phase.

The timing is particularly delicate. Redcare’s stock has been on a rollercoaster, closing Tuesday at €48.54. While it has rallied roughly 46% over the past 30 days, it remains 64% below its 52-week high of €136.20 and has shed more than 62% of its value over the past year. The Relative Strength Index (RSI) stands at 19.3, indicating deeply oversold conditions, while the stock’s annualized volatility hovers near 80%.

Preliminary Numbers Impress, but the Full Picture Is Pending

Redcare’s preliminary first-quarter figures already painted a rosy picture. Group revenue jumped 18.3% to €848 million, with prescription (Rx) sales surging 35% to €315 million. The German Rx business was the standout, growing 55%. Active customers reached 14.2 million. Yet these are top-line numbers only. The full quarterly report on May 6 will be the real test, revealing the adjusted EBITDA margin, free cash flow, and whether the heavy investment cycle is beginning to yield returns.

The company has already lowered its medium-term margin target from over 8% to more than 5%, a revision that has weighed on the stock. For 2026, it still expects revenue growth of 13% to 15%, German Rx volumes above €670 million, and an adjusted EBITDA margin of at least 2.5%. The investment rate is projected to fall below 2% of revenue once the current cycle ends.

Tech Edge Meets Competitive Pressure

On the technology front, Redcare scored a first-mover advantage in April by integrating the new TI 2.0 telematics infrastructure, replacing physical health cards with digital identities. This speeds up e-prescription access and improves scalability. With a 67% market share in Germany’s online Rx segment, the company holds a commanding position.

But the over-the-counter (OTC) segment is under siege. dm launched its “dm-med” platform in December 2025, and Rossmann is planning a similar move. The threat of margin erosion in non-prescription sales is a growing concern for investors.

Analyst Divergence Reflects Uncertainty

The analyst community is split on Redcare’s prospects. Jefferies maintains a €150 price target with a “Buy” rating, and Deutsche Bank also recommends buying, citing rising e-prescription market share. Barclays, however, recently slashed its target from €110 to €70, though it kept an “Overweight” rating. The wide gap between €70 and €150 underscores the debate over whether growth can outpace margin compression.

The May 6 report will be the first hard data point to test whether Redcare’s investment cycle is generating measurable returns—or if the margin story continues to lag behind the revenue surge. The leadership shake-up only adds to the stakes.